Sculptra

Injectable poly-L-lactic acid (PLLA) is world-famous filler used in lipoatrophy and facial rejuvenation because of its collagen neogenesis effect which leads to gradual volume restoration. Until recently, quite a number of unwanted adverse events of PLLA have been reported. However, to the best of our knowledge, paraffinoma as a complication of PLLA has never been reported. We herein describe the first case of paraffinoma after Sculptra® injection and propose its possible mechanism.

A survey of Sculptra® Aesthetic injectors was conducted to understand how the product is being currently reconstituted and injected. Questions were asked of injectors to understand their reasons for choice and volume of diluent(s), additions, and time for the reconstitution process. These results are discussed in the context of the past history of the product over the last decade, with a focus on adverse events such as papules and nodules. <br /><br /> <em>J Drugs Dermatol. </em>2016;15(6):759-762...

Treatment guidelines are a crucial part of every medical aesthetic practice and must be in place before utilizing aesthetic medical injectables. An "Aesthetic Policy and Procedure Manual" features specific details (e.g., patient assessment, indication, contraindications, warnings and precautions, injection techniques, documentation, etc.) around dermal fillers (e.g., Restylane, Juvéderm, Voluma), hyaluronidase, neurotoxins (e.g., Botox Cosmetic, Dysport, and Xeomin) and Sculptra. This article describes why an "Aesthetic Policy and Procedure" manual is a necessary tool in every aesthetic provider's armamentarium, what it is composed of, as well as how these guidelines serve as a protective mechanism for the aesthetic provider's clinic if legal action is brought against their staff, their medical director, and/or their clinic...

Injectable fillers have become a prevalent means of facial rejuvenation and volume expansion. While typically well tolerated, serious complications have been reported. The authors present a case in which an otherwise healthy female with a history of multiple filler injections including poly-L-lactic acid, developed 3 weeks of neuropathic pain in the left temporal fossa following injection. To the best of the authors knowledge, neuropathic pain has not been reported as a complication following poly-L-lactic acid injection...

No abstract text is available yet for this article.

Over the last few years, there have been a number of important changes in how we appreciate and understand the aging face. Volume loss is now recognized as a major component of facial aging. Treatment options that replace lost volume are increasingly used for recontouring and rejuvenation of the aging face. In this review we present and discuss the European Expert Group recommendations on the ideal use of the unique collagen stimulator, poly-L-lactic acid (PLLA, Sculptra®, Sinclair Pharmaceuticals) for facial rejuvenation lasting up to 25 months...

INTRODUCTION: Facial aging is a gradual process that involves a complex interaction of multiple factors including cutaneous photodamage and laxity, subcutaneous tissue volume loss, and bony resorption. These features have all been show to significantly improve with intense pulsed light (IPL), microfocused ultrasound (MFUS, Ultherapy), and poly-L-lactic acid (PLLA). METHODS: To review the use of IPL, MFUS, and PLLA in combination with the treatment of facial aging...

Poly-L-lactic acid (PLLA) is a biostimulatory agent that can correct bony and soft tissue facial deficiencies by producing gradual volume restoration. Proper patient selection and clear expectations are important to treatment success. Correct product preparation, injection technique, and patient follow-up correlates with increased patient safety, outcomes, and satisfaction. Alone, or in combination with other rejuvenative procedures, Sculptra® provides longer-lasting improvement to signs of facial aging...

No abstract text is available yet for this article.

UNLABELLED: HIV lipoatrophy is a stigmatizing condition associated with significant psychological morbidity. The aim of this study was to evaluate change in facial volume and psychological morbidity following treatment with autologous fat, Sculptra and Bio-alcamid. METHODS: HIV LD patients were treated based on a clinical assessment in a prospective, observational study. 3-D images were obtained pre-operatively then at 2, 6 and 12 months post-operatively using the DI3D system...

BACKGROUND: Characteristics of the aging face include soft tissue atrophy, loss of skin elasticity resulting in excess facial skin, and gravitational descent or ptosis of facial soft tissues. Poly-L-lactic acid (PLLA) is a synthetic biodegradable polymer that provides soft tissue augmentation through stimulation of an inflammatory tissue response with subsequent collagen deposition. OBJECTIVE: The authors discuss the special considerations inherent in facial aging, describe the mechanism of action and indications for a new PLLA filler under consideration for Food and Drug Administration (FDA) approval (Sculptra Aesthetic, sanofi-aventis US, Bridgewater, New Jersey), and detail the results of a two-year off-label pilot study with the product...

AIM OF THE STUDY: Patients seeking care of facial ageing demand an aesthetic result that appears natural and is very safe, with techniques the less invasive possible. Our series of cases helps analyse the efficiency and safety of L-polylactic acid in the management of facial ageing. PATIENTS AND METHOD: Retrospective analysis of a single series of patients treated with L-polylactic acid (Sculptra™) between September 2000 and September 2007. All patients over 18 years, consulting for facial ageing and/or loss of volume and treated with L-polylactic acid injections, were included in our evaluation...

With demand for minimally invasive cosmetic procedures rising in patients of color, it is becoming increasingly important for clinical dermatologists to be aware of specific needs of these patients. This article therefore reviews considerations for using cosmetic procedures on skin of color, and reports the authors' clinical experience with the use of injectable poly-L-lactic acid (PLLA, Sculptra, Dermik Laboratories, a business of sanofi-aventis U.S. LLC) in this patient population. The authors' experience indicates that patients with skin of color may require an increased interval between treatments; however, with proper attention to patient selection and administration technique, injectable PLLA can be used effectively in this patient group...

Sculptra (Sanofi-Aventis, Bridgewater, NJ) was approved by the U.S. Food Drug Administration (FDA) for use in HIV-related lipoatrophy in 2004 and received FDA approval for cosmetic use as Sculptra Aesthetic in July 2009. The authors have experience with this product in both applications. The purpose of this article is to share their methodology. Both soft-tissue and supraperiosteal injections will be illustrated and discussed in detail. Much progress has been made in the last decade in understanding of volume changes in all structural layers of the face, and this will be briefly reviewed as it is pertinent to the methodology...

Sculptra is a biocompatible, resorbable injectable filler composed of poly-L-lactic acid (PLLA). It falls in the class of a stimulatory filler that creates its effect through encouraging neocollagenesis when injected. As it differs from traditional, static fillers such as hyaluronic acid and collagen, it requires a special understanding of how it works, where it can be used, and how it should be injected. The goal of this article is to review the nature of stimulatory volume replacement with a focus on PLLA and its unique considerations...

This report describes a novel use of injectable poly-L-lactic acid (PLLA; Sculptra) for the correction of acne scars in an adult patient. The patient, a 60-year-old white woman, had previously been treated for acne scars with CO(2) laser resurfacing, dermabrasion and trichloroacetic acid peels, as well as collagen, calcium hydroxylapatite and hyaluronic acid dermal fillers. These treatment approaches did not provide satisfactory improvement of the patient's acne scars. The latest course of therapy consisted of seven treatment sessions during which injectable PLLA was administered serially into individual scars and depressions in the patient's nasolabial folds, mid-cheeks and chin...

BACKGROUND: Deep lines, facial folds, retracted scars, and contour depressions on all areas of the body have typically been resistant to efforts at release. OBJECTIVE: A method using a wire dissector to achieve complete release or subcision of these subdermal attachments with access only through the needle insertion sites is described. METHODS: The wire dissector was inserted into the subcutaneous tissue just below the dermal-subcutaneous tissue junction and brought out of the skin on one side of the defect...

Sculptra (poly-L-lactic acid), a new injectable soft tissue filler designed to stimulate neocollagenesis, increase dermal thickness, and enhance volume, is most commonly used for the midface and temporal fossa, with more limited use in the mental and prejowl areas. In the authors' practice, Sculptra injections have virtually replaced autologous fat transfer, yielding excellent results for patients with mild to moderate midface and jowl laxity.

BACKGROUND: Poly-L-lactic acid (PLLA), marketed as Sculptra (Dermik Laboratories, Bridgewater, NJ), is used for subcutaneous volume restoration. Durability studies are ongoing and longevity data are not yet available. OBJECTIVE: We sought to evaluate the long-term efficacy and safety of PLLA during 3 years of follow-up. METHODS: We conducted a prospective cohort study. Primary outcome measures were facial lipoatrophy score, complications, and patient satisfaction...

The Blue Pacific study assessed the effect of injectable poly-L-lactic acid (PLLA) (Sculptra; Dermik Laboratories, a business of Sanofi-Aventis U.S. LLC, Bridgewater, NJ, USA) for the treatment of human immunodeficiency virus (HIV)-associated facial lipoatrophy. This case report describes a patient treated originally with injectable PLLA in the Blue Pacific study, then retreated with injectable PLLA 12 months after completion of his initial treatment sessions. Retreatment was well tolerated and resulted in a correction of facial lipoatrophy for a duration of 2 years 7 months...